Skip to main content

Advertisement

Table 2 Three years evolution in GnRHa treated and untreated patients with CPP

From: Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment

  Baseline 1 yr 2 yrs 3 yrs
  Treated Untreated Treated Untreated Treated Untreated Treated Untreated After Tx
CA (yr) 7.3 ± 1.5 7.7 ± 0.7 8.3 ± 1.5 8.7 ± 0.9 9.2 ± 1.5 9.6 ± 0.7 10.1 ± 1.5 10.7 ± 1.2 11.04 ± 0.4
Weight (z-score) 1.4 ± 0.7 1.2 ± 0.8 1.4 ± 0.6 1.3 ± 0.8 1.3 ± 0.9 1.2 ± 0.7 1.6 ± 0.6* 0.9 ± 0.5 0.8 ± 0.9
BMI (z-score) 1.2 ± 0.9 1 ± 0.8 1.2 ± 0.7 1.1 ± 0.8 1.1 ± 1 1 ± 0.7 1.3 ± 0.8 0.7 ± 0.5 0.7 ± 0.9
Ob/over (%) 79.3 50 65.4 50 65.4 50 81.8 40 40
Obesity (%) 24.1 25 26.9 25 23.1 25 45.5 0 20
Overweight (%) 55.2 25 38.5 25 42.3 25 36.4 40 20
Glycemia (mg/dl) 73.1 ± 9.1 74 ± 7.6 79.6 ± 8.9 88.6 ± 6.5 76 ± 10.1 84.3 ± 11.7 84.4 ± 5.3 80 ± 2.6 81 ± 18.4
Total-C (mg/dl) 156 ± 31.5 167.6 ± 35.7 172.1 ± 34.8 146.5 ± 42.3 152.8 ± 38.6 177.3 ± 23.9 159.2 ± 26.5 171.7 ± 39.1 167.3 ± 19.4
LDL-C (mg/dl) 96.6 ± 38.1 99.5 ± 16.3 108.1 ± 19.1 71.3 ± 24.1 92.9 ± 30.5 112.5 ± 7.8 100.2 ± 22.8 128.8 ± 13.9 122.5 ± 2.1
HDL-C (mg/dl) 43.8 ± 9 52 ± 7.1 35 ± 10.1 37.3 ± 9 48.5 ± 12.8 37 ± 4.2 43.8 ± 14 45.5 ± 2.1 44.5 ± 14.9
TRG (mg/dl) 83.3 ± 36.2 115.8 ± 78.5 80.9 ± 30.7 90.8 ± 33.7 79.9 ± 46.5 117 ± 66.8 83.3 ± 52.7 98.5 ± 37.5 64 ± 31.1
TRG/HDL-C ratio 2.1 ± 0.8 3 ± 1.5 2.5 ± 1 2.4 ± 0.5 1.7 ± 1.2 2.9 ± 2.2 1.9 ± 1.3 2.2 ± 0.9 2 ± 0.8
  1. Data are expressed as mean ± SDS. SDS denotes the standard-deviation score for age and sex.
  2. After Tx, after treatment; CA, Chronological age; BMI, body mass index; Ob/Over, obesity and overweight rate; Total-C, total cholesterol; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TGR, Triglycerides.
  3. *p 0.02, treated vs. untreated at 3 years of follow up.